Compare UEIC & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | CSBR |
|---|---|---|
| Founded | 1986 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 68.8M |
| IPO Year | 1995 | 2015 |
| Metric | UEIC | CSBR |
|---|---|---|
| Price | $5.55 | $5.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 55.8K | 14.7K |
| Earning Date | 11-05-2026 | 09-10-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | ★ 23.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $368,288,000.00 | $2,900,000.00 |
| Revenue This Year | N/A | $9.83 |
| Revenue Next Year | $1.51 | $8.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.69 | $4.59 |
| 52 Week High | $5.99 | $8.31 |
| Indicator | UEIC | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 67.31 | 49.99 |
| Support Level | $4.12 | $4.71 |
| Resistance Level | $5.67 | $6.31 |
| Average True Range (ATR) | 0.25 | 0.28 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 87.93 | 43.81 |
Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.